[Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU].
The aim of this study was to detect changes of transient evoked otoacoustic emissions (TEOAE) during chemotherapy with cisplatin and fluorouracil (5FU). A review of the literature reveals that the incidence of cisplatin ototoxicity varies from 9% to 50%; this variation is due to differences in doses, duration of administration, to the criteria for ototoxicity and on audiological methods. Three cycles of chemotherapy (1000 mg/m2 5FU from day 1 to 5 and 100 mg/m2 cisplatin on day 1) were given to 12 patients; the OAE were measured before chemotherapy and after each administration. In 86% of the ears measured we found changes in the TEOAE; the mean values for the amplitude of the TEOAE decreased about 13% after the end of the chemotherapy. Pure tone thresholds were reduced in almost 50% of the measured ears. The decrease of amplitude of TEOAE is an early sign of an ototoxic secondary effect, probably due to damage to the outer hair cells. TEOAE is a sensitive method for detecting ototoxicity in cisplatin-treated patients and more reliable than pure-tone audiometry or evoked acoustic potentials.
Beck
A
A
Universitäts-HNO-Klinik Mainz.
Maurer
J
J
Welkoborsky
H J
HJ
Mann
W
W
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003051:Cochlea / Q000187:drug effects*; D003055:Cochlear Microphonic Potentials / Q000187:drug effects*; D005072:Evoked Potentials, Auditory / Q000187:drug effects; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D011930:Reaction Time / Q000187:drug effects
D002945:Cisplatin; D005472:Fluorouracil
Veränderungen transitorisch evozierter otoakustischer Emissionen unter Chemotherapie mit Cisplatin und 5FU.